Terms: = Kidney tumors AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Diagnosis
47 results:
1. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
[No Abstract] [Full Text] [Related]
2. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
3. [Clinicopathological features of intravascular large B-cell lymphoma and collision tumors of five cases].
Liu J; Liu GZ; Xia L; Wang HY; Zhang XF; Liu H
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):22-28. PubMed ID: 38178742
[No Abstract] [Full Text] [Related]
4. Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.
Weinberg OK; Pinkus GC; Ramos-Gonzalez GJ; Agur T; Rodig NM
Clin Transplant; 2023 Dec; 37(12):e15134. PubMed ID: 37772613
[TBL] [Abstract] [Full Text] [Related]
5. Acute kidney injury in patients with cancer receiving anti-PD-1/pd-l1 antibodies: incidence, risk factors, and prognosis.
Lou Q; Gong J; Ye B; Yu R; Bu S; Li Y; Zhu B; Shao L
Ren Fail; 2023 Dec; 45(1):2238823. PubMed ID: 37491871
[TBL] [Abstract] [Full Text] [Related]
6. A
Smith SC; Yu J; Paul AK
Int J Surg Pathol; 2024 May; 32(3):539-542. PubMed ID: 37415407
[TBL] [Abstract] [Full Text] [Related]
7. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract] [Full Text] [Related]
8. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Rouprêt M; Seisen T; Birtle AJ; Capoun O; Compérat EM; Dominguez-Escrig JL; Gürses Andersson I; Liedberg F; Mariappan P; Hugh Mostafid A; Pradere B; van Rhijn BWG; Shariat SF; Rai BP; Soria F; Soukup V; Wood RG; Xylinas EN; Masson-Lecomte A; Gontero P
Eur Urol; 2023 Jul; 84(1):49-64. PubMed ID: 36967359
[TBL] [Abstract] [Full Text] [Related]
9. A lung squamous cell carcinoma-associated membranous nephropathy patient free of tumor and membranous nephropathy after the treatment of surgery and radiochemotherapy following pembrolizumab: A rare case report.
Chen F; Du H; Fang S
Medicine (Baltimore); 2023 Jan; 102(3):e32508. PubMed ID: 36701715
[TBL] [Abstract] [Full Text] [Related]
10. Extranodal NK/T-cell lymphoma: a case report of renal insufficiency during PD1 inhibitor treatment.
Hu HY; Xie XX; Tan ST; Fan X; He J
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3827-3831. PubMed ID: 35731051
[TBL] [Abstract] [Full Text] [Related]
11. Clear Cell Renal Cell Carcinoma with Immunotherapy Effect Mimicking Xanthogranulomatous Pyelonephritis.
Wang Y; Ganesan S; Williamson SR; Rayes-Danan R
Int J Surg Pathol; 2023 May; 31(3):316-320. PubMed ID: 35570589
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent pdl1 expression.
Kammerer-Jacquet SF; Gandon C; Dugay F; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Leroy X; Aubert S; Vermaut C; Escande F; Verkarre V; Compérat E; Ambrosetti D; Pedeutour F; Belaud-Rotureau MA; Rioux-Leclercq N;
Histopathology; 2022 Aug; 81(2):228-238. PubMed ID: 35562857
[TBL] [Abstract] [Full Text] [Related]
13. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract] [Full Text] [Related]
14. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the kidney With Bone Metastases: A Case Report.
Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
[TBL] [Abstract] [Full Text] [Related]
15. Identification of candidate biomarker
Lv Q; Xiao W; Xiong Z; Shi J; Miao D; Meng X; Yuan H; Yang H; Zhang X
Front Biosci (Landmark Ed); 2021 Nov; 26(11):1176-1190. PubMed ID: 34856762
[No Abstract] [Full Text] [Related]
16. Clinicopathological significance of claspin overexpression and its efficacy as a novel biomarker for the diagnosis of urothelial carcinoma.
Kobayashi G; Hayashi T; Sentani K; Babasaki T; Sekino Y; Inoue S; Uraoka N; Hanamoto M; Nose H; Teishima J; Oue N; Matsubara A; Sasaki N; Yasui W
Virchows Arch; 2022 Mar; 480(3):621-633. PubMed ID: 34842980
[TBL] [Abstract] [Full Text] [Related]
17. Assessment of pd-l1 expression in patients with neuroblastoma and renal tumors.
Şener S; Poyraz A; Okur A; Pınarlı FG; Karadeniz C
Turk J Pediatr; 2021; 63(5):758-766. PubMed ID: 34738358
[TBL] [Abstract] [Full Text] [Related]
18. Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.
Wulfken LM; Becker JC; Hayajneh R; Wagner AD; Schaper-Gerhardt K; Flatt N; Grimmelmann I; Gutzmer R
Front Immunol; 2021; 12():733961. PubMed ID: 34675925
[TBL] [Abstract] [Full Text] [Related]
19. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract] [Full Text] [Related]
20.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract] [Full Text] [Related]
[Next]
